gangliosides, in sera is characteristic of autoimmune neuropathies, such as GBS, multifocal motor neuropathy, and IgM paraproteinemic neuropathy (1) . The titer of the antiganglioside antibodies in GBSis highest in the acute-phase serum and decreases with time. This suggests that the production of anti-ganglioside antibodies is closely associated with the pathogenesis of GBS. Anti-ganglioside antibody therefore is a possible humoral factor that plays an important role in the pathogenesis. Molecular mimicry between the microorganism of the antecedent infection and gangliosides is considered to be an important mechanism of the antibody production in GBS. The lipopolysaccharide of Campyiobacterjejuni has been reported to have a ganglioside-like structure (2). In addition to gangliosides, galactocerebroside, a major myelin glycolipid, also is a target for serum antibody in some GBSpatients. Most of GBSpatients with anti-galactocerebroside antibody have an antecedent infection with Mycoplasmapneumoniae, which has been shown to have a glycolipid with a galactocerebroside-like carbohydrate structure (3).
Most of the anti-ganglioside antibodies are known to be associated with a certain clinical features. Anti-GQlb IgG antibody is closely associated with ophthalmoplegia and ataxia (MFS) (4, 5). Anti-GMl IgG antibody (6), anti-GalNAc-GDla IgG antibody (7), and anti-GMlb IgG antibody (8) are associated with pure motor type of GBS. Anti-GDIa IgG antibody is associated with GBSof acute motor axonal neuropathy type (9). GBS patients with anti-GDlb IgG antibody have sensory as well as motor disturbance and are of demyelinating type (10). IgG antibody against LM1 is present in the sera from patients with demyelinating type of GBS. The association between anti-GTla IgG antibody and the pharyngeal-cervical-brachial variant of GBShas been reported.
Someof these relationships can be explained by the distribution of target antigens in human peripheral nerves; that is, GQlb is densely localized in the paranodal region of the three cranial nerves (oculomotor, trochlear, and abducens nerves) innervating extraocular muscles (4) and in some primary sensory neurons (5), GDlb is localized in the large primary sensory neurons and in the paranodal region of the peripheral nerves (1 1). LM1is known to be the predominant ganglioside in humanperipheral nervous system myelin. Anti-ganglioside antibodies maytherefore determine the distribution of the damage by binding to the regions where respective ganglioside antigens are densely localized.
The pathogenetic role of anti-ganglioside antibodies has been confirmed by rabbit experimental sensory ataxic neuropathy induced by sensitization with GDlbganglioside (12). GDlb is localized in large primary sensory neurons, which convey deep sensation. Disturbance in deep sensation cause sensory ataxia. Anti-GDlb antibody therefore may bind to those GDlb-positive sensory neurons to cause ataxia. In addition, motor neuropathy has been reported by sensitization with GM1(13). The effect of anti-GQlb antibody to the neurotransmitter release from the presynaptic terminal of neuromuscular junction of mouse diaphragm has also been reported (14). Thus, data suggesting that anti-ganglioside antibody is involved in the pathogenesis of autoimmune neuropathies have recently accumulated.
Anti-ganglioside antibodies also can be used as a diagnostic marker of autoimmune neuropathies, especially GBSand MFS, because early diagnosis is essential for appropriate therapy for the patients with GBSand MFS. For example, acute ophthalmoplegia or ataxia can be caused by manydis-Internal Medicine Vol. 42, No. 6 (June 2003) orders of various etiologies; cerebrovascular diseases, acute cerebellitis, brainstem encephalitis, multiple sclerosis, aneurysm, tumor, Tolosa-Hunt syndrome, diabetic ophthalmoplegia, myasthenia gravis, etc. In such cases, anti-GQlb IgG antibody can be used as a diagnostic marker of MFSand GBSwith ophthalmoplegia or ataxia. The presence of anti-ganglioside antibodies is usually examined by enzyme-linked immunosorbent assay (ELISA) or thin-layer chromatogram (TLC) immunostaining procedure.
Although those assays could be performed within one day, they need technical skill and are not included in the routine laboratory examination in most hospitals. Considering the usefulness of the antibody assay for the diagnosis of GBS, it is of importance to develop a method that can be easily performed by clinicians. Alaedini and Latov reported the latex agglutination assay for detection of anti-ganglioside antibodies (15). In this issue, Irie et al reported the results of antiganglioside antibody assay by the use of the above method with some modifications and compared the results with those of ELISA (16).
See also p 490.
This method is easy to perform and the results can be obtained within only a few minutes. The problem is its sensitivity. Anti-ganglioside antibodies with a high titer on ELISA were detected by this method, while those with medium or low titer were undetectable. Because this agglutination assay is a hopeful method for easy and rapid examination of antiganglioside antibody activities, further investigation is necessary to increase the sensitivity of this assay.
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